May 2012 Briefing - DermatologyLast Updated: June 01, 2012.
Here are what the editors at HealthDay consider to be the most important developments in Dermatology for May 2012. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.
Slow-Growing Melanomas Lose Structure, Vary Color With Time
THURSDAY, May 31 (HealthDay News) -- The diameter of most slow-growing melanomas (SGMs) changes very little over time, but the lesions can become more disorganized, less structured, and change or develop new colors, according to a study published in the June issue of the British Journal of Dermatology.
Acne Medication Isotretinoin Increases Risk of Eye Disorders
WEDNESDAY, May 30 (HealthDay News) -- The acne medicine isotretinoin may be linked to a nearly two-fold increased risk of ocular adverse effects in users, according to a study published online April 16 in the Archives of Dermatology.
NSAID Use Linked to Reduced Risk of Skin Cancer
TUESDAY, May 29 (HealthDay News) -- Nonsteroidal anti-inflammatory drugs (NSAIDs), including nonselective NSAIDs and older cyclooxygenase (COX)-2 inhibitors, are associated with a decreased risk of squamous cell carcinoma (SCC) and malignant melanoma (MM), particularly among long-term and high-intensity NSAID users, according to a study published online May 29 in Cancer.
Common Therapies for Basal Cell Carcinoma Offer Similar Survival
FRIDAY, May 25 (HealthDay News) -- For patients with superficial basal cell carcinoma (sBCC), treatment with imiquimod or photodynamic therapy (PDT) results in similar long-term tumor-free survival, according to a review published online May 21 in the British Journal of Dermatology.
Vemurafenib, Dabrafenib Linked to Cutaneous Side Effects
THURSDAY, May 24 (HealthDay News) -- The selective small molecule inhibitors of BRAF, vemurafenib and dabrafenib, are associated with diverse cutaneous side effects, including both malignant and benign growths, when used to treat patients with melanoma with the BRAF V600E mutation, according to research published online May 21 in the Journal of the American Academy of Dermatology.
Emily Y. Chu, M.D., Ph.D., of the Hospital of the University of Pennsylvania in Philadelphia, and colleagues evaluated the cutaneous adverse effects of vemurafenib and dabrafenib in 13 patients being treated for metastatic melanoma and one patient being treated for metastatic thyroid cancer.
Hair Loss Pathology Identified in Pityriasis Versicolor Lesions
TUESDAY, May 22 (HealthDay News) -- Patients with pityriasis versicolor (PV) lesions may experience hair thinning and/or loss within the lesion, according to a study published online May 10 in the Journal of the American Academy of Dermatology.
Vigorous Physical Activity Tied to Reduced Psoriasis Risk
TUESDAY, May 22 (HealthDay News) -- Vigorous physical activity is associated with a reduced risk of psoriasis in women, according to a study published online May 21 in the Archives of Dermatology.
Dabrafenib Safe, Active Against Some Metastatic Melanomas
MONDAY, May 21 (HealthDay News) -- Dabrafenib, the mutant BRAF-selective inhibitor of BRAF kinase, is safe for treating solid tumors and shows antitumor activity against Val600-mutant BRAF melanomas and other solid tumors, including melanomas that have metastasized to the brain, according to a study published in the May 19 issue of The Lancet.
Epidemiology of Rosacea Described in United Kingdom
FRIDAY, May 18 (HealthDay News) -- The incidence of rosacea in the United Kingdom is 1.65 per 1,000 person-years, with alcohol consumption linked to a modest increase in risk and current smoking linked to an decreased risk, according to a study published online May 5 in the British Journal of Dermatology.
Sunscreen Ingredient May Be Linked to Risk of Endometriosis
FRIDAY, May 18 (HealthDay News) -- Benzophenone (BP)-type derivatives may be linked to an increased risk of endometriosis, according to a study published in the April 17 issue of Environmental Science & Technology.
PET More Sensitive Than CT for Merkel Cell Carcinoma
TUESDAY, May 15 (HealthDay News) -- Fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) is significantly more sensitive and equally specific compared with traditional computed tomography (CT) imaging for evaluation of the regional lymph node basin in patients with Merkel cell carcinoma (MCC), according to research published online May 2 in the Journal of the American Academy of Dermatology.
Higher Melanoma Mutation Rate Tied to Chronic Sun Exposure
FRIDAY, May 11 (HealthDay News) -- Metastatic melanomas from patients with chronic sun exposure have higher mutation rates, and a single gene is mutated in 14 percent of metastatic melanomas, according to a study published online May 9 in Nature.
Sun Protective Behavior on the Rise in U.S. Adults
THURSDAY, May 10 (HealthDay News) -- Adults in the United States may be taking more precautions to avoid sunburn outdoors, but many are still getting burned, and a substantial proportion are utilizing indoor tanning, according to research published in the May 11 issue of the U.S. Centers for Disease Control and Prevention's Morbidity & Mortality Weekly Report.
Sun/Skin Cancer Counseling Recommended for Youth
TUESDAY, May 8 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) recommends that physicians counsel children, adolescents, and young adults who have fair skin about ultraviolet radiation exposure and skin cancer prevention, according to new recommendations published online May 7 in the Annals of Internal Medicine.
Methodological Heterogeneity Seen in Clinical Trials
TUESDAY, May 1 (HealthDay News) -- Clinical studies registered with ClinicalTrials.gov from 2007 and 2010 are predominately small, single-center trials and contain significant heterogeneity in methodology, according to a study published in the May 2 issue of the Journal of the American Medical Association.
Food Allergy Risk Up for Children Born in the Fall
TUESDAY, May 1 (HealthDay News) -- Children born in the fall have an increased risk of food allergy, with a significantly increased risk seen only for Caucasians and those with eczema, according to a study published online April 19 in Allergy.
Women Have Clear Melanoma Survival Advantage Over Men
TUESDAY, May 1 (HealthDay News) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.
|Previous: May 2012 Briefing - Cardiology||Next: May 2012 Briefing - Diabetes & Endocrinology|
Reader comments on this article are listed below. Review our comments policy.